ATB-2100 Advanced Therapy Bioreactor commercial launch

Pennsylvania-based ABEC commercially launched the ATB-2100, a closed and automated single-use bioreactor platform designed to scale cell expansion from preclinical work through commercial manufacturing.

The ATB-2100 uses ABEC's hollow-fiber perfusion membrane network to deliver nutrients and gases while removing metabolic waste. ABEC says the platform maintains a consistent membrane surface-area-to-volume ratio across bioreactor volumes from 200 milliliters to 10 liters and has demonstrated expansion of T-cells, induced pluripotent stem cells, and mesenchymal stem cells.

Headline metrics

Scale range	200 mL to 10 L	Company-stated bioreactor volume range
Launch state	Commercial launch	Announced Nov. 5, 2026

Highlights

Manufacturing applicationCell and gene therapy cell-expansion processing from preclinical development through commercial manufacturing
U.S. nexusABEC is headquartered in Bethlehem, Pennsylvania and provides biopharmaceutical manufacturing systems

Resources

ABEC product launchabec.com
ABEC ATB-2100 product pageabec.com